2,493
Views
39
CrossRef citations to date
0
Altmetric
Original Articles

A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity

, , , , , , , , & show all
Pages 1-12 | Received 11 Jan 2018, Accepted 13 Apr 2018, Published online: 18 May 2018

References

  • RepassGLPalmerWCStancampianoFFHand, foot, and mouth disease: identifying and managing an acute viral syndromeClevel. Clin. J. Med.201481 537 54310.3949/ccjm.81a.13132
  • VentarolaDBordoneLSilverbergNUpdate on hand-foot-and-mouth diseaseClin. Dermatol.20153334034610.1016/j.clindermatol.2014.12.011
  • WongSSYipCCLauSKYuenKYHuman enterovirus 71 and hand, foot and mouth diseaseEpidemiol. Infect.20101381071108910.1017/S0950268809991555
  • SolomonTVirology, epidemiology, pathogenesis, and control of enterovirus 71Lancet Infect. Dis.20101077879010.1016/S1473-3099(10)70194-8
  • MaoQCoxsackievirus A16: epidemiology, diagnosis, and vaccineHum. Vaccines Immunother.20141036036710.4161/hv.27087
  • BianLCoxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwideExpert Rev. Anti Infect. Ther.2015131061107110.1586/14787210.2015.1058156
  • LuQBCirculation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011PLoS One20127e5207310.1371/journal.pone.00520733525556
  • BlomqvistSCo-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in FinlandJ. Clin. Virol.201048495410.1016/j.jcv.2010.02.002
  • MirandAOutbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational studyClin. Microbiol. Infect.201218E110E11810.1111/j.1469-0691.2012.03789.x
  • MirandAAmbulatory pediatric surveillance of hand, foot and mouth disease as signal of an outbreak of coxsackievirus A6 infections, France, 2014–2015Emerg. Infect. Dis.2016221884189310.3201/eid2211.1605905088007
  • WuYThe largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strainsInt. J. Infect. Dis.201014e1076e108110.1016/j.ijid.2010.07.006
  • KobayashiMClinical manifestations of coxsackievirus A6 infection associated with a major outbreak of hand, foot, and mouth disease in JapanJpn J. Infect. Dis.20136626026110.7883/yoken.66.260
  • MiyamotoAAn outbreak of hand-foot-and-mouth disease mimicking chicken pox, with a frequent association of onychomadesis in Japan in 2009: a new phenotype caused by coxsackievirus A6Eur. J. Dermatol.201424103104
  • MontesMHand, foot, and mouth disease outbreak and coxsackievirus A6, northern Spain, 2011Emerg. Infect. Dis.20131967667810.3201/eid1904.1215893647425
  • PuenpaJHand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012Emerg. Infect. Dis.20131964164310.3201/eid1904.1216663647428
  • HanJFHand, foot, and mouth disease outbreak caused by coxsackievirus A6, China, 2013J. Infect.20146930330510.1016/j.jinf.2014.03.015
  • WeiSHAn outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010BMC Infect. Dis.20111110.1186/1471-2334-11-3463297538
  • HuangCCNeurologic complications in children with enterovirus 71 infectionN. Engl. J. Med.199934193694210.1056/NEJM199909233411302
  • LeeTCDiseases caused by enterovirus 71 infectionPediatr. Infect. Dis. J.20092890491010.1097/INF.0b013e3181a41d63
  • FuschinoMEDetection of coxsackievirus A10 in multiple tissues of a fatal infant sepsis caseJ. Clin. Virol.20125325926110.1016/j.jcv.2011.12.011
  • WangCYFatal coxsackievirus A16 infectionPediatr. Infect. Dis. J.20042327527610.1097/01.inf.0000115950.63906.78
  • YangFSevere hand, foot, and mouth disease and coxsackievirus A6-Shenzhen, ChinaClin. Infect. Dis.2014591504150510.1093/cid/ciu624
  • KleinMChongPIs a multivalent hand, foot, and mouth disease vaccine feasible?Hum. Vaccines Immunother.2015112688270410.1080/21645515.2015.1049780
  • AswathyrajSArunkumarGAlidjinouEKHoberDHand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategyMed. Microbiol. Immunol.201620539740710.1007/s00430-016-0465-y
  • YiEJEnterovirus 71 infection and vaccinesClin. Exp. Vaccin. Res.2017641410.7774/cevr.2017.6.1.4
  • CaiYActive immunization with a coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infectionVaccine2013312215222110.1016/j.vaccine.2013.03.007
  • ShenCVirus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infectionsVaccine2016344025403110.1016/j.vaccine.2016.06.028
  • ShenCInactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challengeVaccine2016345005501210.1016/j.vaccine.2016.08.033
  • LiuQA virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challengeVaccine2012306642664810.1016/j.vaccine.2012.08.071
  • LiuQTongXHuangZTowards broadly protective polyvalent vaccines against hand, foot and mouth diseaseMicrobes Infect.20151715516210.1016/j.micinf.2014.11.004
  • KleinMHEV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccinesExpert Rev. Vaccines20151433734010.1586/14760584.2015.993385
  • RoldaoAVirus-like particles in vaccine developmentExpert Rev. Vaccines201091149117610.1586/erv.10.115
  • KushnirNStreatfieldSJYusibovVVirus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical developmentVaccine201231588310.1016/j.vaccine.2012.10.083
  • KuZA virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in miceVaccine2014324296430310.1016/j.vaccine.2014.06.025
  • ChungYCExpression, purification and characterization of enterovirus-71 virus-like particlesWorld J. Gastroenterol.20061292192710.3748/wjg.v12.i6.9214066158
  • GongMCryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine developmentJ. Virol.2014886444645210.1128/JVI.00200-144093858
  • KuZNeutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment stepsPLoS One20138e5760110.1371/journal.pone.00576013579802
  • LiCWangJCTaylorMWZlotnickAIn vitro assembly of an empty picornavirus capsid follows a dodecahedral pathJ. Virol.201286130621306910.1128/JVI.01033-123497625
  • ZhangCHigh-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in miceVaccine2015332335234110.1016/j.vaccine.2015.03.034
  • CaineEAEfficacy of a trivalent hand, foot, and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in miceViruses201575919593210.3390/v71129164664989
  • LiuCCImmunological and biochemical characterizations of coxsackievirus A6 and A10 viral particlesAntivir. Res.2016129586610.1016/j.antiviral.2016.02.008
  • CollerBAClementsDEDengue vaccines: progress and challengesCurr. Opin. Immunol.20112339139810.1016/j.coi.2011.03.005
  • ChokephaibulkitKPerngGCChallenges for the formulation of a universal vaccine against dengueExp. Biol. Med. (Maywood)201323856657810.1177/1535370212473703
  • LinYLEnterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particlesVaccine2012301305131210.1016/j.vaccine.2011.12.081
  • ChungYCImmunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challengeVaccine2008261855186210.1016/j.vaccine.2008.01.058
  • KuZShiJLiuQHuangZDevelopment of murine monoclonal antibodies with potent neutralization effects on enterovirus 71J. Virol. Methods201218619319710.1016/j.jviromet.2012.06.025
  • ZhouYYeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in miceAntivir. Res.201613216516910.1016/j.antiviral.2016.06.004
  • ReedLJMuenchHA simple method of estimating fifty per cent endpointsAm. J. Epidemiol.19382749349710.1093/oxfordjournals.aje.a118408
  • LiuQDetection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteinsJ. Virol. Methods201117311512010.1016/j.jviromet.2011.01.016